沉静了快4年之久的医药板块,最近可算是“炸窝”了。前脚全球制药公司管线规模第八的恒瑞医药宣布一项总额高达120亿美元的全球合作协议,后脚新药研发服务平台药明康德发布年中喜报:上半年收入、归母净利润分别同比增加20.6%、95.5%;更乐观的是,公司还上调了全年业绩指引:预计2025年持续经营业务收入重回双位数增长,增速从10-15%上调至13-17%;预计全年整体收入从人民币415-430亿元上调...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.